• new product

Mediso receives FDA approval for InterViewÔäó nuclear medicine image processing software

PRNewswire June 21, 2023

BUDAPEST, Hungary, June 21, 2023 /PRNewswire/ — Mediso has announced the Food and Drug Administration (FDA) clearance of the InterViewÔäó FUSION and InterViewÔäó XP multimodality (PET/SPECT/MRI/CT) image processing and reporting software which is specifically adapted for nuclear medicine and molecular imaging workflows.




The vendor independent┬áInterViewÔäó software offers a complete solution for image visualization, post-processing and reporting specifically adapted for the routine nuclear medicine and molecular imaging workflow. Workflows and specialized tools cover the most common nuclear medicine studies including bone, cardiac, central nervous system, thyroid, parathyroid, kidney, liver, digestive system and lung. Fast and standardized reporting is available for all nuclear medicine procedures. The software improves SPECT image quality with iterative reconstruction and reach absolute quantitation with Tera-TomoÔäó┬áSPECT reconstruction engine, making fast and accurate personalized dosimetry possible. It also features a variety of state-of-the-art modules to enhance clinical and preclinical research work such as automatic lesion detection, and automatic segmentation and image denoising.┬áThe┬áInterViewÔäó software seamlessly integrates to any hospital information system either running on stand-alone workstation, or on physical or virtualized server.

“Receiving the FDA nod for our image processing software marks the next step in marketing our clinical products in the USA,” said Istvan Bagamery, founder and CEO of Mediso. “The InterViewÔäó software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application and they demonstrate our continuous commitment to the molecular imaging market.”

Mediso, works in the field of medical imaging for 30+ years with a profile of development, manufacturing, selling and servicing standalone and multi-modality imaging devices. The company offers complete solutions from hardware design to evaluation and quantification software for clinical patient care and preclinical research.

Mediso has a leader position in the clinical nuclear medicine market with over 1500 commissioned systems around the world. Beyond the market leading AnyScan TRIO SPECT/CT, Mediso also offers an integrated SPECT/PET/CT triple modality system that is unique on the market.

Products are sold directly or through a distribution network in 100+ countries worldwide.


Cision View original content:https://www.prnewswire.com/apac/news-releases/mediso-receives-fda-approval-for-interview-nuclear-medicine-image-processing-software-301855428.html


AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.